- SB-505124
-
- $34.00 / 1mg
-
2026-01-16
- CAS:694433-59-5
- Min. Order:
- Purity: 98.74%
- Supply Ability: 10g
|
| | 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride Basic information |
| Product Name: | 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride | | Synonyms: | 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride;SB-505124 hydrate hydrochloride;2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-iMidazol-4-yl)-6-Methylpyridine;2-[4-(1,3-Benzodioxol-5-yl)-2-(1,1- diMethylethyl)-1H-iMidazol-5-yl]-6-Methyl-pyridine;2-[4-(1,3-Benzodioxol-5-yl)-2-(tert-butyl)-1H-imidazol-5-yl]-6-methylpyridine;SB-505124, 98%, a selective inhibitor of TGFβR for ALK4, ALK5;SB-505124 hydrochloride hydrate;2-(4-(benzo[d][1,3]dioxol-5-yl)-2-tert-butyl-1H-imidazol-5-yl)-6-methylpyridine | | CAS: | 694433-59-5 | | MF: | C20H21N3O2 | | MW: | 335.4 | | EINECS: | | | Product Categories: | Inhibitors;Smad;TGF-beta;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors | | Mol File: | 694433-59-5.mol | ![2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride Structure](CAS/GIF/694433-59-5.gif) |
| | 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride Chemical Properties |
| Melting point | 168 °C | | Boiling point | 509.7±50.0 °C(Predicted) | | density | 1.202 | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO: >10mg/mL | | form | powder | | pka | 11.26±0.10(Predicted) | | color | yellow | | InChI | 1S/C20H21N3O2.ClH.H2O/c1-12-6-5-7-14(21-12)18-17(22-19(23-18)20(2,3)4)13-8-9-15-16(10-13)25-11-24-15;;/h5-10H,11H2,1-4H3,(H,22,23);1H;1H2 | | InChIKey | DIDCCMVWCVRTNB-UHFFFAOYSA-N | | SMILES | O.Cl.Cc1cccc(n1)-c2[nH]c(nc2-c3ccc4OCOc4c3)C(C)(C)C |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | HS Code | 29349990 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride Usage And Synthesis |
| Description | SB-505124 inhibits the TGF-β1 receptor serine/threonine kinase ALK5 with an IC50 value of 47 nM. Though it is a less potent antagonist of ALK4 (IC50 = 129 nM) and ALK7, SB-505124 selectively and concentration-dependently inhibits ALK4-, ALK5-, and ALK7-dependent activation of downstream SMAD2 and SMAD3 and TGF-β–induced MAP kinase pathway components without altering ALK1-3 or ALK6-induced SMAD signaling. In an assay determining in vitro phosphorylation of SMAD3, SB-505124 is more potent than SB-431452 with IC50 values of 47 versus 94 nM, respectively. | | Uses | SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less potency. SB-505124 blocks TGF-β–induced apoptosis of FaO cells and NRP 154 cells in a concentration-dependent manner. SB-505124 has been shown to suppress the migration and invasion of breast cancer MCF-7-M5 cells. | | Uses | SB-505124 inhibits the TGF-β1 receptor serine/threonine kinase ALK5 with an IC50 value of 47 nM. Though it is a less potent antagonist of ALK4 (IC50 = 129 nM) and ALK7, SB-505124 selectively and concentration-dependently inhibits ALK4-, ALK5-, and ALK7-dependent activation of downstream SMAD2 and SMAD3 and TGF-β–induced MAP kinase pathway components without altering ALK1-3 or ALK6-induced SMAD signaling. In an assay determining in vitro phosphorylation of SMAD3, SB-505124 is more potent than SB-431452 with IC50 values of 47 versus 94 nM, respectively. | | Uses | SB-505124 hydrochloride hydrate was used to study the role of TGF-β pathway in development and differentiation studies.3,4 | | Definition | ChEBI: SB 505124 is a member of the class of imidazoles carrying tert-butyl, 1,3-benzodioxol-5-yl and 6-methylpyridin-2-yl substituents at positions 2, 4 and 5 respectively. It has a role as a TGFbeta receptor antagonist. It is a member of imidazoles, a benzodioxole and a member of methylpyridines. | | Biochem/physiol Actions | SB-505124 selectively inhibits TGF-β type I receptors, activin receptor-like kinases (ALK) 4, 5 and 7. It inhibits ALK4-, 5- and 7-mediated activation of Smad2, Smad3 and MAPK pathway induced by TGF-β.1 SB-505124 inhibits the human fibroblast trans-differentiation induced by the co-culture with Esophageal squamous cell carcinoma.2 | | storage | Store at -20°C | | References | [1] STACEY DACOSTA BYFIELD. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.[J]. Molecular Pharmacology, 2004, 65 3: 744-752. DOI: 10.1124/mol.65.3.744
[2] JENNIFER SAPITRO. Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor.[J]. Molecular Vision, 2010: 1880-1892.
|
| | 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrate hydrochloride Preparation Products And Raw materials |
|